Skip to main content

Table 1 Baseline demographics and patient characteristics

From: Intravenous abatacept in Japanese patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study

Baseline characteristic Patients
(N = 20)
Age, years 10.5 (5–16)
Age group, n (%)
 4–8 years 8 (40)
 9–12 years 7 (35)
 13–17 years 5 (25)
Weight, kg 37.9 (15.4–68.3)
Female, n (%) 15 (75)
Race: Japanese, n (%) 20 (100)
Disease duration, years 0.75 (0.2–11.9)
Number of active joints 6.0 (2.0–19.0)
Number of joints with LOM 4.0 (2.0–10.0)
Parent Global Assessment, VAS 100 mm 37.5 (0–94.0)
Physician Global Assessment, VAS 100 mm 37.0 (10–80.0)
CHAQ-DI 0.63 (0–2.88)
CRP, mg/dL 0.58 (0.02–2.67)
JADAS27-CRP 12.0 (4.2–26.4)
JIA disease subtype at study entry, n (%)
 Extended oligoarticular 2 (10)
 Polyarticular (RF negative) 8 (40)
 Polyarticular (RF positive) 10 (50)
 Systemic 0
Prior biologic therapy, n (%) 4 (20)
 Tocilizumab 3 (15)
 Anti-TNF therapy 4 (20)
  Adalimumab 4 (20)
  Etanercept 1 (5)
Concomitant MTX therapy at Day 1, n (%) 16 (80)
 MTX dose, mg/m2/week 8.9 (6.0–10.3)
  1. Data are median (minimum–maximum) unless specified otherwise
  2. CHAQ-DI Childhood Health Assessment Questionnaire-Disability Index, JADAS27-CRP juvenile arthritis disease activity score 27 active joint count-C-reactive protein, JIA juvenile idiopathic arthritis, LOM limitation of motion, MTX methotrexate, RF rheumatoid factor, SD standard deviation, TNF tumor necrosis factor, VAS visual analog scale